A randomized, double-blind, placebo-controlled trial of CDP571, a humanized monoclonal antibody to tumour necrosis factor-alpha, in patients with corticosteroid-dependent Crohn's disease

Clicks: 315
ID: 269350
2005
Article Quality & Performance Metrics
Overall Quality Improving Quality
0.0 /100
Combines engagement data with AI-assessed academic quality
AI Quality Assessment
Not analyzed
Abstract
The CDP571 was effective for corticosteroid-sparing at week 16 but not week 10, and was well-tolerated in patients with corticosteroid-dependent Crohn's disease.
Reference Key
bg2005alimentarya Use this key to autocite in the manuscript while using SciMatic Manuscript Manager or Thesis Manager
Authors Feagan BG;Sandborn WJ;Baker JP;Cominelli F;Sutherland LR;Elson CO;Salzberg BA;Archambault A;Bernstein CN;Lichtenstein GR;Heath PK;Cameron S;Hanauer SB;;
Journal alimentary pharmacology & therapeutics
Year 2005
DOI
DOI not found
URL
Keywords

Citations

No citations found. To add a citation, contact the admin at info@scimatic.org

No comments yet. Be the first to comment on this article.